Name: Scientific Session: Advanced Stages
Start: 2022-10-24T07:30
End: 2022-10-24T09:00
Location: Großer Saal

07:30 – 09:00

Room: Großer Saal

Scientific Session Advanced Stages

Olivier Casasnovas
John Radford

07:30–07:35
Why I recommend BV-AVD
- Ranjana Advani
07:35–07:40
Why I recommend PET-guided ABVD
- Alexander Fosså
07:40–07:45
Why I recommend PET-adapted escalated BEACOPP
- Peter Borchmann
07:45–08:30
Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective
- Martin Dreyling
- Jack Richardson
- Sarah Wells
08:30–08:35
WS Report: Learning through International Collaboration
- Peter Borchmann
- Alison Moskowitz
08:35–08:47
- Abstract Talk
FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
- Wouter Plattel
08:47–09:00
- Abstract Talk
Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
- Peter Borchmann

09:15 – 10:15

Room: Großer Saal

Scientific Session Special Situations in HL

Richard Hoppe
Marie Jose Kersten

09:15–09:35
HL in Pregnancy
- Daan Dierickx
09:35–09:55
HIV-positive HL
- Otavio Baiocchi
09:55–10:15
alloSCT in the era of anti-PD1
- Anna Sureda

10:30 – 12:00

Room: Großer Saal

Scientific Session Genomics, Biology and Microenvironment

Wolfram Klapper
Ralf Küppers

10:30–10:53
Biological Classification of HL by Liquid Biopsy
- Sven Borchmann
10:53–11:16
Single Cell Transcriptomics of HL
- Christian Steidl
WS Report: Bringing Liquid Biopsy to Patients
- Sven Borchmann
- Davide Rossi
- Abstract Talk
Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
- Kristiina Karihtala
- Abstract Talk
High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
- Arjan Diepstra
- Abstract Talk
Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
- Julia Paczkowska

12:15 – 13:45

Room: Großer Saal

Satellite Symposium (by Takeda Pharmaceuticals USA, Inc.) Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

Graham Collins
Alex Herrera
Pier Luigi Zinzani

12:15–12:20
Welcome and introduction
- Graham Collins
12:20–12:30
Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1
- Graham Collins
12:30–13:30
Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)
- Graham Collins
- Alex Herrera
- Pier Luigi Zinzani
13:30–13:40

Audience Q&A
13:40–13:45
Summary and close
- Graham Collins

14:00 – 15:30

Room: Großer Saal

Scientific Session Relapsed / Refractory HL

Ranjana Advani
Craig H. Moskowitz

14:00–14:23
1ˢᵗ Relapse of HL
- Craig H. Moskowitz
14:23–14:46
Novel developments in R/R HL
- Graham Collins
14:46–14:51
WS Report: PET beyond Deauville
- Sally Barrington
- Martin Hutchings
- Carsten Kobe
14:51–15:04
- Abstract Talk
Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
- Anna Sureda
15:04–15:17
- Abstract Talk
High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
- Alison Moskowitz
15:17–15:30
- Abstract Talk
Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
- Catherine Diefenbach

15:30 – 16:00

Room: Großer Saal

Main Program Closing Remarks

15:30–16:00
Conference Highlights
- Ranjana Advani

16:00 – 16:30

Room: Foyer (First Floor)

Program: Monday (24.10.2022)

07:30 – 09:00

Scientific Session Advanced Stages

Why I recommend BV-AVD

Why I recommend PET-guided ABVD

Why I recommend PET-adapted escalated BEACOPP

Discussion forum: Challenging standard recommendations from a patient's, nurse's and physician's perspective

WS Report: Learning through International Collaboration

FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

09:15 – 10:15

Scientific Session Special Situations in HL

HL in Pregnancy

HIV-positive HL

alloSCT in the era of anti-PD1

10:30 – 12:00

Scientific Session Genomics, Biology and Microenvironment

Biological Classification of HL by Liquid Biopsy

Single Cell Transcriptomics of HL

WS Report: Bringing Liquid Biopsy to Patients

Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade

12:15 – 13:45

Satellite Symposium (by Takeda Pharmaceuticals USA, Inc.) Bridging the gap between efficacy and toxicity in the frontline treatment of stage IV Hodgkin lymphoma

Welcome and introduction

Hot off the press: The latest data for the frontline treatment of patients with Stage IV CD30+ Hodgkin Lymphoma from ECHELON-1

Bridging the gap: Balancing efficacy and toxicity in three challenging case studies (A debate and audience discussion with our panel)

Audience Q&A

Summary and close

14:00 – 15:30

Scientific Session Relapsed / Refractory HL

1ˢᵗ Relapse of HL

Novel developments in R/R HL

WS Report: PET beyond Deauville

Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.

High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)

15:30 – 16:00

Main Program Closing Remarks

Conference Highlights

16:00 – 16:30

Main Program Farewell

Archive